Vnitr Lek 2014, 60(9):791-796

Diabetes mellitus and pancreatic cancer - cause or result?

Alena ©mahelová
Diabetologické centrum, vedoucí doc. MUDr. Alena ©mahelová, III. interní gerontometabolická klinika LF UK a FN Hradec Králové, přednosta prof. MUDr. Luboą Sobotka, CSc.

Incretin glucagon like peptid-1 receptor agonists are also known as incretin mimetics. These are the new drugs for the treatment of type 2 diabetes, which have a significant antihyperglycemic effect. For the individual treatment can be used short-acting and long-acting drugs. In addition to glucose effect there are influenced another factors, especially weight and hypertension. The patophysiological mechanism of their action, pharmacological and clinical differences and their use in clinical practice are described.

Keywords: glucagon-like peptid 1; glucagon-like peptid 1 agonists short-acting, long-acting; clinical effects

Received: July 13, 2014; Accepted: July 17, 2014; Published: September 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©mahelová A. Diabetes mellitus and pancreatic cancer - cause or result? Vnitr Lek. 2014;60(9):791-796.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Petrie JR. The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc Diabetol 2013; 12: 130. Dostupné z DOI: <http://doi:10.1186/1475-2840-12-130>. Go to original source... Go to PubMed...
    2. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35(6): 1364-1379. Go to original source... Go to PubMed...
    3. Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 2002; 45(7): S23-S28. Go to original source...
    4. de Pablos-Velasco P, Bradley C, Eschwege E et al. The PANORAMA pan-European survey: glycaemic control and treatment patterns in patients with type 2 diabetes. Diabetologia 2010; 53(Suppl 1): Abstract 1012. Go to PubMed...
    5. Viberti G, Kahn SE, Greene DA et al. A Diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25(10): 1737-1743. Go to original source... Go to PubMed...
    6. Nauck MA, Heimesaat MM, Behle Ket al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87(3): 1239-1246. Go to original source... Go to PubMed...
    7. Hansen L, Hartmann B, Bisgaard T et al. Somatostatin restrains the secretion of glucagon-like peptide 1 and 2 from isolated perfused porcine ileum. Am J Physiol Endocrinol Metab 2000; 278(6): E1010-E1018. Go to original source... Go to PubMed...
    8. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8(12): 728-742. Go to original source... Go to PubMed...
    9. Tschen SI, Dhawan S, Gurlo T et al. Age-dependent decline in β-cell proliferation restricts the capacity of β-cell regeneration in mice. Diabetes 2009; 58(6): 1312-1320. Go to original source... Go to PubMed...
    10. Bunck MC, Cornér A, Eliasson B et al. Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011; 34(9): 2041-2047. Go to original source... Go to PubMed...
    11. Nikolaidis LA, Mankad S, Sokos GG et al. Effects of glucagon-like peptide 1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109(8): 962-965. Go to original source... Go to PubMed...
    12. DeYoung MB, MacConell L, Sarin V et al. Encapsulation of exenatide in poly-(d,l-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 2011; 13(11): 1145-1154. Go to original source... Go to PubMed...
    13. Schwarz S. Evidence-Based Practice use of incretine based therapy in the natural history of diabetes. Postgrad Med 2014; 126(3): 66-84. Go to original source... Go to PubMed...
    14. Gerich J. Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. Int J Gen Med 2013; 6: 877-95. Dostupné z DOI: <http://doi:10.2147/IJGM.S51665>. Go to original source... Go to PubMed...
    15. Vilsbøll T, Zdravkovic M, Le-Thi T et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30(6): 1608-1610. Go to original source... Go to PubMed...
    16. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010; 33(11): 2349-2354. Go to original source... Go to PubMed...
    17. Steinberg WM et al. Longitudinal monitoring of lipase and amylase in adults with type 2 diabetes and obesity: evidence from two phase 3 randomized clinical trials with the once-daily GLP-1 analog liraglutide [poster presentation at Digestive Disease Week 2012]. Gastroenterology 2012; 142(Suppl 1): S93-S91. Go to original source...
    18. Butler PC, Matveyenko AV, Dry S et al. Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire? Diabetologia 2010; 53(1): 1-6. Go to original source... Go to PubMed...
    19. Matveyenko AV, Dry S, Cox HI et al Beneficial endocrine but adverse exocrine effect of sitagliptin in the HIP rat model of type 2 diabetes, interactions with metformin. Diabetes 2009; 58(7): 1604-1615. Go to original source... Go to PubMed...
    20. Informace dostupné z WWW: <http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/07/news_detail_001856.jsp∣=WC0b01ac058004d5c1>.
    21. Bjerre Knudsen L, Madsen LW, Andersen S et al. Glucagon-like peptide 1 receptor agonists activate rodent thyroid C cells causing calcitonin release and C cell proliferation. Endocrinology 2010; 151(4): 1473-1486. Go to original source... Go to PubMed...
    22. Nauck MA, Friedrich N. Do GLP-1-Based Therapies Increase Cancer Risk? Diabetes Care 2013; 36(Suppl 2): S245-S252. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.